2005

1. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point

   International Journal of Antimicrobial Agents, Vol. 25, Núm. 2, pp. 163-167